Basic Colofac Information

• INN (International Nonproprietary Name): Mebeverine
• Brand Names Available In Canada (English): Not Specified
• ATC Code: A03AA04 — Drugs for functional gastrointestinal disorders, synthetic anticholinergics, esters with tertiary amino group.
• Forms & Dosages: Standard tablets 135 mg (1 tablet three times daily); Prolonged-release capsules 200 mg (1 capsule twice daily); Oral liquid equivalent for swallowing difficulties.
• Manufacturers In Canada (English): Not Specified. Major global originator/suppliers: Abbott Laboratories/Mylan (now Viatris), Teva, Sanofi, Zentiva, Mylan Australia and several generics from India/Asia.
• Registration Status In Canada (English): Not Specified. Internationally registered with MHRA (UK), Medsafe (New Zealand), and TGA (Australia).
• OTC / Rx Classification: OTC in some EU/UK pharmacies for small packs; prescription-only in many other countries including Australia and Eastern Europe.

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients often ask whether recent trials changed how colofac or mebeverine is used for IBS.

Recent evidence from 2022–2024 shows limited high-quality randomised controlled trial data specifically for mebeverine.

Systematic reviews through 2023 found modest benefit for antispasmodics overall but inconsistent superiority of mebeverine versus placebo.

No large multicentre Canadian randomised controlled trials were published between 2022 and 2024.

Regulatory real-world signals from the UK and Australasia maintain established safety profiles while reporting mixed efficacy.

Main Outcomes

Head-to-head comparisons increasingly favour peppermint oil or combined dietary interventions such as a low FODMAP approach in many centres.

Mebeverine still shows symptomatic benefit for a subset of patients, especially for focal cramp relief.

Safety Observations

Post-marketing surveillance from 2022–24 reaffirmed rare hypersensitivity and occasional central nervous system effects such as dizziness and headache.

Very rare ocular events were reported, consistent with historical product information.

Clinical implication for Canada: clinicians may consider mebeverine where anticholinergics are contraindicated, while prioritizing dietary and psychological interventions first.

Clinical Mechanism Of Action

Layman’s Explanation

People want to know how colofac helps gut pain without heavy anticholinergic side effects.

Mebeverine relaxes gut muscle spasms to reduce crampy abdominal pain commonly seen in IBS.

The medicine works locally in the gut and usually does not cause classic systemic anticholinergic effects like dry mouth or blurred vision.

Scientific Breakdown

Mebeverine is classified under ATC A03AA04 as a synthetic anticholinergic ester with a tertiary amino group.

Despite this classification, the clinical profile lacks prominent antimuscarinic side effects suggesting a local smooth-muscle relaxant action.

Site Of Action

The primary site of action is the smooth muscle of the gastrointestinal tract, where abnormal motility and spasm are reduced.

Pharmacological Class (ATC A03AA04)

Mechanisms proposed include calcium channel modulation, membrane-stabilising effects and direct action on enteric smooth muscle.

Oral formulations provide local gut effect with limited central nervous system penetration.

Typical dosing provides a local concentration sufficient for symptomatic relief in many patients who report fewer systemic anticholinergic complaints.

Scope Of Approved & Off-Label Use

Health Canada Approvals (DIN-Based)

Common question: Is colofac approved and listed in Canada like in the UK or Australia?

Internationally, Colofac (mebeverine) is licensed mainly for irritable bowel syndrome and gut spasm relief in several jurisdictions.

Health Canada DIN status for specific brands must be verified before dispensing because national registration in Canada is not specified in the product information.

Mebeverine is not a widely marketed staple on provincial formularies and coverage varies by province.

Notable Off-Label Trends In Canadian Practice

Canadian prescribers may use mebeverine off-label for chronic functional abdominal pain or spasm-predominant IBS when first-line measures are incomplete.

Pediatric use is generally not recommended under 10 years, and elderly dosing is usually unchanged but monitored clinically.

Regulatory nuance: the UK allows small-pack OTC supply while other markets remain prescription-only, so pharmacists should confirm importation rules and DIN presence.

Dosage Strategy

General Dosing Per Health Canada Monographs

One of the first questions is how to take Colofac for IBS cramps.

Adults commonly take 135 mg tablets three times daily or 200 mg modified-release capsules twice daily depending on formulation.

Children under 10 years are generally advised not to use mebeverine because safety and efficacy are not established.

Elderly patients usually receive standard adult dosing, with clinical monitoring for frailty or comorbidity.

Condition-Specific Dosing Adjustments

There are no formal dose adjustments for hepatic or renal impairment in product monographs, but exercise caution in severe impairment due to limited data.

Treatment duration is symptom dependent and can be several weeks to months; reassess if no benefit after about two weeks.

Missed-dose advice: take when remembered unless near the next dose, do not double up.

Overdose is rarely serious; provide symptomatic treatment and arrange medical assessment if severe effects occur.

Safety Protocols

Contraindications (Canadian Advisories)

Patients commonly ask what would make colofac unsafe to take.

Absolute contraindications include hypersensitivity to mebeverine or any excipients and known paralytic ileus.

Certain formulations are contraindicated in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Relative cautions include severe liver or kidney impairment, pregnancy, breastfeeding and acute porphyrias.

Adverse Effects (Post-Market Reports)

Adverse effects are generally rare and mild, including hypersensitivity reactions like rash, urticaria, and oedema.

Gastrointestinal complaints such as diarrhoea or constipation and CNS symptoms like dizziness or headache have been reported.

Very rare events include drug-induced angle-closure glaucoma and false-positive urine amphetamine screens.

Pharmacists should screen for contraindications, advise stopping and seeking urgent care for severe abdominal pain, and report suspected adverse events to Canada Vigilance.

Interaction Mapping

Food Interactions Common In Canadian Diet

Many patients ask whether diet affects how well colofac works.

Mebeverine has no major documented interactions with food in product information.

However Canadian dietary patterns high in caffeine, alcohol, or fatty meals can aggravate IBS symptoms and change perceived response.

Advise patients to monitor triggers and combine pharmacotherapy with dietary measures when appropriate.

Drug Combinations Flagged By Health Canada

Product monographs list no major pharmacokinetic interactions for mebeverine.

Caution is reasonable with other agents that affect gut motility or with CNS depressants due to possible additive effects.

Consider anticholinergic burden when patients are on multiple medicines and review OTC herbal remedies such as peppermint oil for combined antispasmodic effect.

Pharmacists should check full medication lists including OTCs and naturopathic remedies available at national chains.

Patient Experience Analysis

Canadian Survey Data

Patients want to know how likely colofac is to help them based on local experience.

Formal Canadian RCT patient-level data are limited, so evidence from small clinics and pharmacy feedback matters for real-world expectations.

Clinic surveys and pharmacy reports from 2020–24 show heterogeneous responses with a portion of patients reporting clear cramp relief and others noting minimal change.

Forum & Community Pharmacy Trends

Community pharmacists at chains such as Shoppers Drug Mart, Rexall and London Drugs note frequent enquiries about antispasmodics and interest in peppermint oil and dietary options.

Online forums often describe Colofac as well tolerated with few systemic side effects but variable effectiveness and access issues due to importation or DIN uncertainty.

Pharmacists advise trial periods of two to eight weeks, symptom tracking, and combining treatment with low FODMAP guidance and psychological therapies where relevant.

Distribution & Pricing Landscape

National Pharmacy Chains

Availability of Colofac and mebeverine generics in Canada is variable between pharmacies and provinces.

Major chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs may stock comparable antispasmodics but branded Colofac depends on supplier contracts and DIN status.

Online Pharmacy Availability & Provincial Restrictions

Licensed Canadian online pharmacies sometimes list imported mebeverine; always verify DIN and Canadian shipping compliance before purchasing.

Provincial formularies like ODB, BC PharmaCare and RAMQ rarely list mebeverine as a standard benefit and coverage is generally exceptional-access only.

In our online pharmacy, colofac is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

List prices in the US or UK can look lower, but importation fees, dispensing charges and compliance checks often offset savings.

Bilingual labelling, Health Canada import rules and DIN confirmation affect legal access and cost for Canadian patients.

Pharmacists should counsel patients to buy from licensed suppliers to reduce counterfeit risk and to confirm reimbursement pathways when needed.

Alternative Options

Comparison Table Of DIN-Approved Alternatives

When colofac is unsuitable, several alternatives are commonly used in Canada.

Dicyclomine (dicycloverine/Bentyl®), hyoscine butylbromide (Buscopan® where available), peppermint oil (Colpermin®), and alverine citrate (Spasmonal®) are typical choices.

Non-pharmacological options include the low FODMAP diet, CBT and gut-directed hypnotherapy which increasingly lead in guideline recommendations.

Pros And Cons Checklist

Mebeverine: generally well tolerated with unclear consistent superiority over placebo.

Dicyclomine: effective but has anticholinergic effects that some patients cannot tolerate.

Hyoscine: quick relief for some but risk of dry mouth and constipation.

Peppermint oil: evidence supports IBS pain reduction and it is available OTC in many markets.

Choose mebeverine for patients seeking minimal anticholinergic burden and consider diet-first strategies for long-term management.

Regulatory Status

Health Canada Approval Process

Health Canada requires a Drug Identification Number (DIN) for marketed pharmaceuticals in Canada.

Prescribers and pharmacists should verify the DIN and product monograph before dispensing mebeverine-containing products.

Internationally, mebeverine brands are authorised by MHRA, Medsafe and TGA with varying OTC versus prescription statuses.

DIN And Bilingual Labelling Rules

Products sold in Canada must meet English/French labelling requirements where marketed.

Importation of Colofac or generics into Canada must comply with Health Canada regulations and applicable provincial reimbursement rules.

Adverse events are reportable to Canada Vigilance and a DIN influences provincial formulary listing decisions.

Consolidated FAQ

Below are common questions Canadian patients ask at the pharmacy counter.

Q1: Is Colofac available in Canada and covered by provincial drug plans?

A1: Availability is variable; check the Health Canada Drug Product Database for DIN and provincial formularies such as ODB, PharmaCare and RAMQ for coverage details.

Q2: How quickly will mebeverine work for IBS cramps?

A2: Some patients report relief within days but clinicians commonly reassess after about two weeks to judge benefit.

Q3: Is mebeverine safe during pregnancy or breastfeeding?

A3: Data are insufficient; avoidance is suggested unless clinically indicated and benefit outweighs risk—discuss with a prescriber.

Q4: Can mebeverine be used long-term?

A4: It is non-habit forming and may be used under supervision for months with monitoring of effectiveness and adverse effects.

Q5: Where to buy safely in Canada?

A5: Use licensed community pharmacies or Canadian online pharmacies that verify DIN and product monograph, or consult pharmacists at major chains.

Visual Guide

Patients often appreciate a quick reference to dosing and access.

Suggested infographic elements include a dosage quick-card showing 135 mg tablet TID versus 200 mg MR capsule BID and missed-dose instructions.

Include a provincial coverage map noting likely non-listing on ODB, PharmaCare and RAMQ with exceptional access guidance.

Add a purchase channels flowchart: community pharmacy → licensed Canadian online pharmacy → international import with DIN checks.

Safety callouts should list contraindications like hypersensitivity and paralytic ileus, pregnancy/breastfeeding caution, and Canada Vigilance reporting details.

Storage pictogram should indicate store below 25°C, protect from moisture and keep out of reach of children.

Design notes: bilingual labels, pharmacist counselling prompts and a QR code linking to the Health Canada Drug Product Database improve patient confidence at point-of-sale.

Storage & Transport

Canadian Household Guidelines

Patients frequently ask how to store colofac at home.

Store mebeverine products in their original blister pack below 25°C and protect from moisture and light.

Keep medicines in a cool, dry place away from bathrooms and sinks and out of reach of children and pets.

Do not use after the expiry date printed on the pack.

Cold-Chain Storage Where Applicable

Mebeverine does not require refrigeration and no cold-chain logistics are necessary for routine supply.

For imported products, confirm storage conditions during transit and ensure bilingual labelling where required.

Dispose of unused medication through provincial take-back programs or return to a pharmacy to prevent diversion.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Patients often want a simple plan they can follow at home.

Counsel patients to take 135 mg three times daily or 200 mg modified-release twice daily depending on the formulation supplied.

Advise a trial period of a few weeks while tracking symptom frequency and severity in a diary.

Screen for contraindications like paralytic ileus and allergy before starting therapy and document counselling.

Refer patients promptly for urgent review if red-flag signs occur such as worsening abdominal pain, fever or GI bleeding.

Provincial Health Authority Guidance

Check provincial drug information for reimbursement routes such as exceptional access and for any local formularies or preferred alternatives.

For brand switches or travel, verify DIN and bioequivalence and provide bilingual counselling handouts when required.

When effectiveness is limited, liaise with prescribers to consider alternatives such as peppermint oil or diet-directed care and psychological therapies.

Delivery Across Canada (English)

City	Region	Delivery Time
Toronto	Ontario	5-7 days
Montréal	Quebec	5-7 days
Vancouver	British Columbia	5-7 days
Calgary	Alberta	5-7 days
Edmonton	Alberta	5-7 days
Ottawa	Ontario	5-7 days
Winnipeg	Manitoba	5-7 days
Halifax	Nova Scotia	5-7 days
Victoria	British Columbia	5-7 days
Hamilton	Ontario	5-9 days
Saskatoon	Saskatchewan	5-9 days
St. John’s	Newfoundland and Labrador	5-9 days